ダウンロード数: 0
このアイテムのファイル:
このアイテムは一定期間後に公開されます。
公開日については,アイテム画面の「著作権等」でご確認ください。
公開日については,アイテム画面の「著作権等」でご確認ください。
タイトル: | Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials |
著者: | Kuroda, Yutaka https://orcid.org/0000-0003-0746-0280 (unconfirmed) Kawai, Toshiyuki Okuzu, Yaichiro Morita, Yugo Matsuda, Shuichi |
著者名の別形: | 黒田, 隆 河井, 利之 奥津, 弥一郎 森田, 侑吾 松田, 秀一 |
キーワード: | Avascular necrosis cell therapy clinical trial osteonecrosis of the femoral head regenerative therapy registry |
発行日: | Apr-2024 |
出版者: | Taylor & Francis |
誌名: | Expert Opinion on Investigational Drugs |
巻: | 33 |
号: | 4 |
開始ページ: | 405 |
終了ページ: | 414 |
抄録: | Introduction: Osteonecrosis of the femoral head (ONFH) is a refractory disease requiring joint replacement in young patients. Regenerative therapies have been developed. Areas covered: This study surveyed clinical trials on regenerative medicine for ONFH. We extracted clinical trials on non-traumatic ONFH from the websites of five publicly available major registries (EuropeanUnion Clinical Trials Register ([EU-CTR], ClinicalTrials.gov, Chinese ClinicalTrial Registry [ChiCTR], University Hospital Medical InformationNetwork - Clinical Trial Registry [UMIN-CTR] and Australian New Zealand Clinical Trials Registry [ANZCTR]).The trials were classified into six categories based on purpose: surgical treatment, non-drug conservative treatment, conservative drug treatment, therapeutic strategy, diagnosis and pathogenesis, and regenerative therapy.) We extracted 169 clinical trials on ONFH. Of these, 37 were on regenerative medicine, including 29 on cell therapy. Surgical treatment was the most common treatment, followed by regenerative therapy.There were 9 clinical trials registered in the EU-CTR, with 5 on regenerative medicine; 79 trials registered on ClinicalTrials.gov, with 24 on regenerativemedicine; 54 trials registered in the ChiCTR, with 6 on regenerative medicine. Expert opinion: The focus of the joint-preserving surgery has shifted to regenerative therapy based on using cell therapy in early-stage ONFH. The global standardisation of regenerative therapy is still ongoing. |
著作権等: | This is an Accepted Manuscript of an article published by Taylor & Francis in [Expert Opinion on Investigational Drugs] on 05 Mar 2024, available at: https://doi.org/10.1080/13543784.2024.2326622 The full-text file will be made open to the public on 05 Mar 2025 in accordance with publisher's 'Terms and Conditions for Self-Archiving'. This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 |
URI: | http://hdl.handle.net/2433/287624 |
DOI(出版社版): | 10.1080/13543784.2024.2326622 |
PubMed ID: | 38431280 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。